Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/21567
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChan, Arlene-
dc.contributor.authorBUYSE, Marc-
dc.contributor.authorYao, Bin-
dc.date.accessioned2016-06-28T13:14:45Z-
dc.date.available2016-06-28T13:14:45Z-
dc.date.issued2016-
dc.identifier.citationLANCET ONCOLOGY, 17 (5), p. E176-E177-
dc.identifier.issn1470-2045-
dc.identifier.urihttp://hdl.handle.net/1942/21567-
dc.language.isoen-
dc.publisherELSEVIER SCIENCE INC-
dc.titleNeratinib after trastuzumab in patients with HER2-positive breast cancer Reply-
dc.typeJournal Contribution-
dc.identifier.epageE177-
dc.identifier.issue5-
dc.identifier.spageE176-
dc.identifier.volume17-
local.format.pages3-
local.bibliographicCitation.jcatA1-
dc.description.notes[Chan, Arlene] Breast Canc Res Ctr Western Australia, Perth, WA, Australia. [Buyse, Marc] Int Inst Drug Dev, San Francisco, CA USA. [Buyse, Marc] Hasselt Univ, I BioStat, Hasselt, Belgium. [Yao, Bin] Puma Biotechnol Inc, Los Angeles, CA USA.-
local.publisher.placeNEW YORK-
local.type.refereedRefereed-
local.type.specifiedLetter-
dc.identifier.isi000374829800006-
item.fulltextWith Fulltext-
item.accessRightsRestricted Access-
item.fullcitationChan, Arlene; BUYSE, Marc & Yao, Bin (2016) Neratinib after trastuzumab in patients with HER2-positive breast cancer Reply. In: LANCET ONCOLOGY, 17 (5), p. E176-E177.-
item.validationecoom 2017-
item.contributorChan, Arlene-
item.contributorBUYSE, Marc-
item.contributorYao, Bin-
crisitem.journal.issn1470-2045-
crisitem.journal.eissn1474-5488-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
chan 1.pdf
  Restricted Access		Published version144.07 kBAdobe PDFView/Open    Request a copy
Show simple item record

WEB OF SCIENCETM
Citations

5
checked on May 10, 2024

Page view(s)

6
checked on Sep 5, 2022

Download(s)

4
checked on Sep 5, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.